Monte Rosa Therapeutics Alternatives & Competitors
12 companies similar to Monte Rosa Therapeutics — Monte Rosa Therapeutics is a clinical-stage biotechnology company developing hig...
Companies similar to Monte Rosa Therapeutics
Relay Therapeutics
Integrating leading-edge computational and experimental science to transform human health....
Cambridge, United States
Orum Therapeutics
A public biotechnology company pioneering a novel class of protein degraders.
Lexington, United States
Differentiated Therapeutics Inc
What if you could predict molecules to make the cause of disease disappear?
San Diego, United States
Anavo Therapeutics BV
UNLOCKING THE PHOSPHATASE TARGET CLASS
Leiden, The Netherlands
Rival Readout
Competing with Monte Rosa Therapeutics? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Avenzo Therapeutics
Developing the next generation of oncology therapies for patients
San Diego, United States
Automera
Empowering the next evolution in degradation platforms.
Singapore, Singapore
Oxford BioTherapeutics
Redefining the cancer-immune synapse for novel immune checkpoint mechanisms
Oxford, United Kingdom
Arcus Biosciences
Biopharmaceutical company developing differentiated molecules and combination therapies fo...
Hayward, United States
Biotheryx, Inc.
Degrading proteins. Saving lives. Building the leader in next-generation targeted protein...
San Diego, United States
Alentis Therapeutics
We develop breakthrough treatments for Claudin1-positive tumors and organ fibrosis
Allschwil, Switzerland
Ventus Therapeutics
Pioneering a unique approach to structure-based drug discovery. Located in Waltham, MA and...
Waltham, United States
Bicycle Therapeutics
Precision-Guided Therapeutics
Cambridge, United Kingdom
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, founded in 2018, is a United States-based clinical-stage biotechnology company at the forefront of developing highly selective molecular glue degrader (MGD) medicines. These innovations target patients with serious conditions across oncology, autoimmune, and inflammatory diseases. The company's...
Discovery and development of molecular glue degraders (MGDs), Research on protein degradation for medical therapeutics, Innovation in AI and structural biology for drug discovery
Pharmaceutical companies, Healthcare providers, Medical researchers, Investors in biotechnology
Clinical-stage, Molecular Glue Degraders, Oncology, Autoimmune Diseases, Inflammatory Diseases, QuEEN Discovery Engine, AI-guided Chemistry, Chemical Libraries, Structural Biology, Proteomics, Protein Degradation, Therapeutic Development, Selective Drug Design, Targeted Therapy
B2B, B2D
Licensing, Performance Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Monte Rosa Therapeutics: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Monte Rosa Therapeutics on 15 Jun 2026. The 12 companies listed here were last checked between 28 Jan 2026 and 8 Nov 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
